Smithkline Beecham Corporation

Merck + Co., Inc.

Glaxo Group Limited

Aventis Pharmaceuticals Inc.

Glaxosmithkline LLC

Timothy Francis Gallagher

Jerry Leroy Adams

Jeffrey Charles Boehm

John C Lee

Joseph Sisko

Philippe L Durette

Ravi Shanker Garigipati

Irennegbe Kelly Osifo

Peter R Young

Peter William Sheldrake

John Richard White

Susan Mary Thompson

Peter C McDonnell

James E Strickler

Dean E McNulty

John Richard Heys

David W Green

Jeffrey Michael Axten

Zhi-Qiang Peng

William Henry Miller

Steven David Knight

Bruce E Witzel

Paul E Bender

Kathleen M Rupprecht

Dashyant Dhanak

Allan N Tischler

Daniel F Veber

Christopher J Burns

Scott Kevin Thompson

Dennis Shinji Yamashita

Neil David Pearson

Graham Elgin Jones

David Thomas Davies

Israil Pendrak

Debra L Allison

Stacie Marie Halbert

Marvin M Goldenberg

Robert A Daines

Renee Louise DesJarlais

Thomas Joseph Carr

Hye-Ja Oh

Ravishanker Garigipati

Zhi Qiang Peng

John Cheung-Lun Lee

Jack Hwekwo Yen

William R Ewing

Tsung-Ying Shen

Alfred P Spada

Wei He

Heinz W Pauls

Mark Andrew Seefeld

Michael R Myers

Stephen M Condon

Kent W Neuenschwander

Joseph M Karpinski

Thomas R Beattie

Neil W Johnson

Robert D Groneberg

Brian W Metcalf

Robert L Morris

Shu S Yang

Yong Mi Choi-Sledeski

Aiwen Li

Daniel Gerard McGarry

Domingos J Silva

Jiri Kasparec

Deborah Lynne Bryan

Gregory Bernard Poli

David Harold Drewry

Barbara Hanney

Jean-Francois Sabuco

William P Dankulich

Michael R Becker

Mark A Bobko

John Ziqi Jiang

Ruth Judik Mayer

Francis A Volz

Thomas H Faitg

Roderick S Davis

Jeffrey M Ralph

Wan F Lau

Stanley J Schmidt

Mark Anthony Seefeld

The present invention relates to a compound represented by the following formula: or a pharmaceutically acceptable salt thereof;

Anthranilamide inhibitors of aurora kinase

Cyclohexane and cyclohexene derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly man.

Antibacterial compounds

Quinoline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans.

Antibacterial agents

This invention is directed to oxoazaheterocycyl compounds which inhibit Factor Xa, to oxoazaheterocycyl compounds which inhibit both Factor Xa and Factor IIa, to pharmaceutical compositions comprising these compounds, to intermediates useful for preparing these compounds, to a method of directly inhibiting Factor Xa and to a method of simultaneously directly inhibiting Factor Xa and Factor IIa.

Substituted oxoazaheterocyclyl compounds

Piperidine derivatives and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man. The piperidine derivatives include compounds of formula (I): wherein R, AB, n, R, Rand Rare defined herein. For example, Ris an optionally substituted bicyclic carbocyclic or heterocyclic ring system, and Ris a group U-Rin which Ris an optionally substituted bicyclic heterocyclic ring system as defined herein (e.g. optionally substituted pyrido [3,2, -b][1,4] thiazin-yl).

Compounds

The present invention relates to sulfonamides, pharmaceutical compositions containing them, and their use as antagonists of urotensin II.

Sulfonamides

Novel pyridyl and pyrimidinyl substituted pyrazole and pyrazoline compounds and compositions for use in therapy.

Pyrazole and pyrazoline substituted compounds

Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.

Compounds of heteroaryl substituted imidazole, their pharmaceutical compositions and uses

Novel 2,4,5-triaryl imidazole compounds and compositions for use in therapy.

Novel 1,4,5-subsituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.

Substituted imidazole compounds

This invention is directed to an (aminoiminomethyl or aminomethyl)benzoheteroaryl compound of formula I which is useful for inhibiting the activity of Factor Xa by combining said compound with a composition containing Factor Xa. The present invention is also directed to compositions containing compounds of the formula I, methods for their preparation, their use, such as in inhibiting the formation of thrombin or for treating a patient suffering from, or subject to, a disease state associated with a physiologically detrimental excess amount of thrombin.

Substituted (aminoiminomethyl or aminomethyl) benzoheteroaryl compounds

Pyrimidine compounds useful in treating cytokine mediated diseases

Amino substituted pyrimidine containing compounds

Growing community of inventors

Harleysville, PA, United States of America

Timothy Francis Gallagher